Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
soluble heparin-binding epidermal growth factor-like growth factor
- Development stage
- Phase 1
- Lead developer
- Trillium Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravesical
01
Overview
TTI-1612 is a recombinant, soluble form of heparin-binding epidermal growth factor-like growth factor (HB-EGF), developed by Trillium Therapeutics. It acts as an HBEGF modulator and is designed to correct dysfunction and restore the bladder epithelium to a normal, healthy state. The drug has been investigated primarily for urogenital diseases such as interstitial cystitis/bladder pain syndrome (IC/BPS) and has also received orphan drug designation in the US and Europe for the prevention of necrotizing enterocolitis (NEC). Its mechanism involves modulation of HBEGF activity, which plays a role in epithelial repair processes[1][2][3][4][8].
- Other names
- soluble HB-EGF like growth factorsoluble heparin-binding epidermal growth factor-like growth factor
02
Targets
EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))HBEGF (Heparin-binding EGF-like growth factor)
Beyond the preview
Go deeper on soluble heparin-binding epidermal growth factor-like growth factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on soluble heparin-binding epidermal growth factor-like growth factor.